Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Below 50-Day Moving Average – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.00 and traded as low as $6.70. Capricor Therapeutics shares last traded at $6.72, with a volume of 1,315,068 shares changing hands.

Wall Street Analysts Forecast Growth

CAPR has been the subject of several analyst reports. B. Riley initiated coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They set a “buy” rating and a $21.00 price target for the company. Alliance Global Partners reissued a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Capricor Therapeutics in a report on Thursday, September 25th. Jones Trading decreased their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, June 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $22.25.

Capricor Therapeutics Trading Down 5.2%

The company’s 50 day moving average is $7.00 and its 200-day moving average is $8.89. The company has a market capitalization of $307.24 million, a P/E ratio of -4.10 and a beta of 0.68.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Sheets Smith Investment Management bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $107,000. First Financial Bank Trust Division bought a new stake in Capricor Therapeutics during the 3rd quarter valued at about $203,000. Tower Research Capital LLC TRC increased its stake in Capricor Therapeutics by 280.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Capricor Therapeutics by 2,342.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company’s stock valued at $361,000 after purchasing an additional 34,908 shares in the last quarter. Finally, Jump Financial LLC increased its stake in Capricor Therapeutics by 42.6% during the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company’s stock valued at $2,309,000 after purchasing an additional 69,515 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.